ACMG Annual Clinical Genetics Meeting 2024 Scientific Platform Presentation

Scientific Platform Presentation

Comprehensive Identification of Gene-Disease Relationships Across the Clinical Exome Through Systematic Literature Review and Parallelized Evidence Curation

Sequencing of large gene panels, exomes and genomes in clinical diagnostics, has led to an exponential increase in the number of variants of uncertain significance. Additionally, with the commoditization of genome sequencing, newly characterized Gene-Disease Relationships (GDRs) are being published at an exponential pace. Despite the great progress made by multiple expert ClinGen working groups in identifying GDRs from >1900 genes, more work remains to fully characterize newly emerging GDRs from the scientific and medical literature and to stay current with the latest published evidence to keep designations up-to-date. For this study, we embarked on massively parallelized curation of all GDRs across all genes associated with the clinical exome using a gene-first approach facilitated by computational indexing of published evidence to ensure maximal sensitivity.

Speaker
Mark J. Kiel, MD, PhD
Chief Scientific Officer & Co-Founder

Mark co-founded Genomenon in 2014 to close the evidence gap in rare disease and cancer. He holds an MD/PhD in Clinical Pathology from the University of Michigan and leads the company's scientific direction.

2024 ACMG Annual Clinical Genetics Meeting
The World’s Most Comprehensive Source of Genomic Evidence

Mastermind accelerates variant interpretation with immediate insight into the full text of millions of scientific articles. Prioritize your search results by clinical relevance and find what you are looking for 5-10 times faster

Explore Mastermind CORE
Every Missing Genetic Variant is a Patient Your Label Doesn't Reach
  • Rare disease and precision oncology programs rely on evidence fragmented across millions of published articles and supplemental datasets.
  • Genomenon builds the custom real-world evidence your program needs.
  • AI-powered search. Expert scientific curation.
  • The result: a broader label, more eligible patients, and a regulatory filing your team can defend.
Request a custom evidence build for your program
speak with an expert